|
Oct 15
|
Orion publishes Interim Report for January–September 2024 and holds a webcast on 29 October 2024
|
|
Oct 14
|
Orion’s collaboration partner Bayer submits application for third indication of darolutamide in the EU
|
|
Jul 25
|
Orion publishes Half-Year Financial Report for January–June 2024 and holds a webcast on 8 August 2024
|
|
Feb 13
|
Notice to the Annual General Meeting of Orion Corporation
|
|
Feb 13
|
Orion Group Financial Statement Release January–December 2023
|
|
Feb 7
|
119,021 Orion Corporation A shares converted into B shares
|
|
Jan 11
|
Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting
|
|
Jan 11
|
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31 million positive impact on Orion’s result in 2023
|
|
Dec 27
|
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
|
|
Dec 4
|
87 000 Orion Corporation A shares converted into B shares
|
|
Aug 22
|
Change in Orion Group Executive Management Board as of February 1st, 2024 – Julia Macharey appointed Senior Vice President, People & Culture
|
|
Jul 4
|
Orion publishes Half-Year Financial Report for January–June 2023 on Monday 17 July 2023
|
|
May 3
|
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
|
|
Apr 28
|
Composition of the Nomination Committee of Orion Corporation
|
|
Apr 27
|
Orion Group Interim Report 1–3/2023
|